Reported Earnings • Aug 16
Second quarter 2026 earnings released: EPS: €1.01 (vs €0.044 loss in 2Q 2025) Second quarter 2026 results: EPS: €1.01 (up from €0.044 loss in 2Q 2025). Revenue: €408.3m (up 33% from 2Q 2025). Net income: €37.7m (up €39.3m from 2Q 2025). Profit margin: 9.2% (up from net loss in 2Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. New Risk • Aug 14
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 64% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 64% per year for the foreseeable future. Minor Risk Paying a dividend despite being loss-making. New Risk • Jul 30
New major risk - Revenue and earnings growth Earnings have declined by 50% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risk Paying a dividend despite being loss-making. Price Target Changed • Jul 16
Price target increased by 39% to €6.25 Up from €4.50, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €6.36. Stock is up 28% over the past year. The company is forecast to post earnings per share of €0.89 next year compared to a net loss per share of €1.04 last year. New Risk • Jul 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.2% average weekly change). Reported Earnings • May 17
First quarter 2026 earnings released: EPS: €0.10 (vs €0.05 in 1Q 2025) First quarter 2026 results: EPS: €0.10 (up from €0.05 in 1Q 2025). Revenue: €310.5m (down 10% from 1Q 2025). Net income: €3.90m (up 106% from 1Q 2025). Profit margin: 1.3% (up from 0.5% in 1Q 2025). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance. Duyuru • Apr 17
H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2026 H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2026, at 10:00 W. Europe Standard Time. Reported Earnings • Apr 06
Full year 2025 earnings released: €1.04 loss per share (vs €0.28 profit in FY 2024) Full year 2025 results: €1.04 loss per share (down from €0.28 profit in FY 2024). Revenue: €1.28b (down 4.8% from FY 2024). Net loss: €38.8m (down 465% from profit in FY 2024). Revenue is forecast to grow 1.8% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Price Target Changed • Jan 28
Price target decreased by 13% to €4.50 Down from €5.20, the current price target is an average from 2 analysts. New target price is 6.4% above last closing price of €4.23. Stock is up 13% over the past year. The company is forecast to post earnings per share of €0.08 for next year compared to €0.29 last year. Reported Earnings • Nov 17
Third quarter 2025 earnings released: €0.02 loss per share (vs €0.09 profit in 3Q 2024) Third quarter 2025 results: €0.02 loss per share (down from €0.09 profit in 3Q 2024). Revenue: €320.0m (down 5.3% from 3Q 2024). Net loss: €662.0k (down 119% from profit in 3Q 2024). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 17
Second quarter 2025 earnings released: €0.04 loss per share (vs €0.037 profit in 2Q 2024) Second quarter 2025 results: €0.04 loss per share (down from €0.037 profit in 2Q 2024). Revenue: €319.9m (down 3.6% from 2Q 2024). Net loss: €1.63m (down 226% from profit in 2Q 2024). Revenue is forecast to stay flat during the next 2 years compared to a 3.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Upcoming Dividend • May 21
Upcoming dividend of €0.10 per share Eligible shareholders must have bought the stock before 28 May 2025. Payment date: 30 May 2025. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.3%). Lower than average of industry peers (3.9%). Reported Earnings • May 16
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: €0.28 (up from €0.28 in FY 2023). Revenue: €1.35b (down 1.1% from FY 2023). Net income: €10.6m (flat on FY 2023). Profit margin: 0.8% (in line with FY 2023). Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 61%. Revenue is forecast to stay flat during the next 2 years compared to a 3.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to €4.97, the stock trades at a trailing P/E ratio of 17.4x. Average forward P/E is 17x in the Chemicals industry in Germany. Total loss to shareholders of 8.3% over the past three years. Price Target Changed • May 11
Price target decreased by 8.8% to €5.20 Down from €5.70, the current price target is provided by 1 analyst. New target price is 31% above last closing price of €3.96. Stock is down 19% over the past year. The company is forecast to post earnings per share of €0.29 for next year compared to €0.29 last year. Duyuru • Apr 17
H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 H&R GmbH & Co. KGaA announced Annual dividend of EUR 0.1000 per share payable on May 30, 2025, ex-date on May 28, 2025 and record date on May 29, 2025. Duyuru • Apr 16
H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2025 H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • Apr 10
Full year 2024 earnings released: EPS: €0.29 (vs €0.28 in FY 2023) Full year 2024 results: EPS: €0.29 (up from €0.28 in FY 2023). Revenue: €1.38b (up 1.0% from FY 2023). Net income: €10.6m (flat on FY 2023). Profit margin: 0.8% (in line with FY 2023). Revenue is forecast to grow 1.9% p.a. on average during the next 2 years, compared to a 4.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €3.59, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Chemicals industry in Germany. Total loss to shareholders of 35% over the past three years. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €4.35, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 16x in the Chemicals industry in Germany. Total loss to shareholders of 33% over the past three years. Reported Earnings • Nov 17
Third quarter 2024 earnings released: EPS: €0.09 (vs €0.20 in 3Q 2023) Third quarter 2024 results: EPS: €0.09 (down from €0.20 in 3Q 2023). Revenue: €348.7m (up 3.4% from 3Q 2023). Net income: €3.52m (down 54% from 3Q 2023). Profit margin: 1.0% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Major Estimate Revision • Oct 15
Consensus revenue estimates fall by 12% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from €1.52b to €1.35b. EPS estimate fell from €0.39 to €0.25 per share. Net income forecast to grow 29% next year vs 59% growth forecast for Chemicals industry in Germany. Consensus price target up from €5.00 to €5.70. Share price was steady at €3.72 over the past week. Reported Earnings • Aug 16
Second quarter 2024 earnings released: EPS: €0.03 (vs €0.13 in 2Q 2023) Second quarter 2024 results: EPS: €0.03 (down from €0.13 in 2Q 2023). Revenue: €347.5m (flat on 2Q 2023). Net income: €1.30m (down 72% from 2Q 2023). Profit margin: 0.4% (down from 1.3% in 2Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €4.14, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 54% over the past three years. Upcoming Dividend • May 22
Upcoming dividend of €0.10 per share Eligible shareholders must have bought the stock before 29 May 2024. Payment date: 31 May 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.0%). Reported Earnings • May 17
First quarter 2024 earnings released: EPS: €0.04 (vs €0.03 loss in 1Q 2023) First quarter 2024 results: EPS: €0.04 (up from €0.03 loss in 1Q 2023). Revenue: €343.7m (down 1.5% from 1Q 2023). Net income: €1.47m (up €2.42m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 30
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: €0.28 (down from €1.15 in FY 2022). Revenue: €1.35b (down 15% from FY 2022). Net income: €10.6m (down 75% from FY 2022). Profit margin: 0.8% (down from 2.7% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 40%. Revenue is forecast to grow 8.0% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Declared Dividend • Mar 30
Dividend of €0.10 announced Dividend of €0.10 is the same as last year. Ex-date: 29th May 2024 Payment date: 31st May 2024 Dividend yield will be 2.1%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (36% earnings payout ratio) and cash flows (4% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 53% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Major Estimate Revision • Dec 20
Consensus EPS estimates increase by 18%, revenue downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €1.32b to €1.27b. EPS estimate rose from €0.565 to €0.665. Net income forecast to grow 69% next year vs 16% growth forecast for Chemicals industry in Germany. Consensus price target of €6.50 unchanged from last update. Share price rose 11% to €4.80 over the past week. Reported Earnings • Aug 18
Second quarter 2023 earnings released: EPS: €0.13 (vs €0.58 in 2Q 2022) Second quarter 2023 results: EPS: €0.13 (down from €0.58 in 2Q 2022). Revenue: €358.1m (down 19% from 2Q 2022). Net income: €4.69m (down 78% from 2Q 2022). Profit margin: 1.3% (down from 4.9% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 17
Upcoming dividend of €0.10 per share at 1.9% yield Eligible shareholders must have bought the stock before 24 May 2023. Payment date: 26 May 2023. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.6%). Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €5.12, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Chemicals industry in Germany. Total returns to shareholders of 24% over the past three years. Buying Opportunity • Apr 26
Now 28% undervalued after recent price drop Over the last 90 days, the stock is down 9.6%. The fair value is estimated to be €7.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to decline by 13% in 2 years. Earnings is forecast to decline by 64% in the next 2 years. Buying Opportunity • Apr 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 2.5%. The fair value is estimated to be €7.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to decline by 12% in 2 years. Earnings is forecast to decline by 64% in the next 2 years. Reported Earnings • Apr 02
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: €1.15 (down from €1.35 in FY 2021). Revenue: €1.58b (up 32% from FY 2021). Net income: €42.7m (down 15% from FY 2021). Profit margin: 2.7% (down from 4.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%. Revenue is expected to decline by 6.7% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.8%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Mar 01
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 3.9%. The fair value is estimated to be €7.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 92%. Revenue is forecast to decline by 9.5% in 2 years. Earnings is forecast to decline by 65% in the next 2 years. Buying Opportunity • Feb 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 7.3%. The fair value is estimated to be €7.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 92%. Revenue is forecast to decline by 9.5% in 2 years. Earnings is forecast to decline by 65% in the next 2 years. Buying Opportunity • Jan 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 6.2%. The fair value is estimated to be €7.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 92%. Revenue is forecast to decline by 9.5% in 2 years. Earnings is forecast to decline by 65% in the next 2 years. Major Estimate Revision • Nov 16
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.73 to €1.01. Revenue forecast unchanged at €1.57b. Net income forecast to shrink 48% next year vs 21% decline forecast for Chemicals industry in Germany. Consensus price target of €6.50 unchanged from last update. Share price was steady at €6.56 over the past week. Reported Earnings • Aug 17
Second quarter 2022 earnings released: EPS: €0.58 (vs €0.64 in 2Q 2021) Second quarter 2022 results: EPS: €0.58 (down from €0.64 in 2Q 2021). Revenue: €453.6m (up 43% from 2Q 2021). Net income: €21.6m (down 8.8% from 2Q 2021). Profit margin: 4.8% (down from 7.5% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11%, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jul 27
Consensus EPS estimates increase by 59% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €1.54b to €1.57b. EPS estimate increased from €0.46 to €0.73 per share. Net income forecast to shrink 54% next year vs 4.5% decline forecast for Chemicals industry in Germany. Consensus price target of €7.25 unchanged from last update. Share price rose 6.0% to €6.40 over the past week. Major Estimate Revision • May 20
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €1.39b to €1.54b. EPS estimate fell from €0.48 to €0.46. Net income forecast to shrink 71% next year vs 3.2% decline forecast for Chemicals industry in Germany. Consensus price target of €7.25 unchanged from last update. Share price fell 2.4% to €5.64 over the past week. Reported Earnings • May 16
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: €0.22 (up from €0.19 in 1Q 2021). Revenue: €368.8m (up 53% from 1Q 2021). Net income: €8.09m (up 12% from 1Q 2021). Profit margin: 2.2% (down from 3.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 6.7%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to €7.25 Down from €8.25, the current price target is provided by 1 analyst. New target price is 25% above last closing price of €5.82. Stock is down 21% over the past year. The company is forecast to post earnings per share of €0.48 for next year compared to €1.35 last year. Major Estimate Revision • Apr 08
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €1.21b to €1.39b. EPS estimate fell from €0.51 to €0.48. Net income forecast to shrink 65% next year vs 4.3% decline forecast for Chemicals industry in Germany. Consensus price target down from €8.50 to €7.25. Share price fell 5.3% to €5.70 over the past week. Reported Earnings • Apr 01
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: €1.35 (up from €0.24 loss in FY 2020). Revenue: €1.19b (up 35% from FY 2020). Net income: €50.2m (up €59.2m from FY 2020). Profit margin: 4.2% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 1.8%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €5.84, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €6.76, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 4.0% over the past three years. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS €0.43 (vs €0.03 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €325.2m (up 56% from 3Q 2020). Net income: €16.0m (up €17.3m from 3Q 2020). Profit margin: 4.9% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 6% per year. Major Estimate Revision • Jul 23
Consensus revenue estimates increase to €1.16b The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from €1.01b to €1.16b. EPS estimate increased from €0.27 to €1.30 per share. Net income forecast to grow 1,239% next year vs 16% growth forecast for Chemicals industry in Germany. Consensus price target up from €8.50 to €11.00. Share price rose 11% to €9.34 over the past week. Reported Earnings • May 17
First quarter 2021 earnings released: EPS €0.19 (vs €0.13 loss in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €248.5m (down 4.2% from 1Q 2020). Net income: €7.24m (up €12.0m from 1Q 2020). Profit margin: 2.9% (up from net loss in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 24
Full year 2020 earnings released: €0.24 loss per share (vs €0.037 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €878.5m (down 19% from FY 2019). Net loss: €9.02m (loss widened €7.65m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Price Target Changed • Feb 03
Price target raised to €6.65 Up from €5.90, the current price target is an average from 2 analysts. The new target price is 9.4% above the current share price of €6.08. As of last close, the stock is up 16% over the past year. Is New 90 Day High Low • Jan 21
New 90-day high: €6.10 The company is up 30% from its price of €4.71 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.12 per share. Is New 90 Day High Low • Jan 05
New 90-day high: €5.75 The company is up 14% from its price of €5.03 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.10 per share. Is New 90 Day High Low • Nov 27
New 90-day high: €5.70 The company is up 9.0% from its price of €5.22 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.38 per share. Analyst Estimate Surprise Post Earnings • Nov 17
Revenue and earnings miss expectations Revenue missed analyst estimates by 16%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 5.7%, compared to a 3.6% growth forecast for the Chemicals industry in Germany. Reported Earnings • Nov 17
Third quarter 2020 earnings released: €0.03 loss per share The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: €213.3m (down 22% from 3Q 2019). Net loss: €1.21m (loss narrowed 80% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 98% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 15
New 90-day low: €4.84 The company is down 19% from its price of €5.97 on 17 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.46 per share. Duyuru • Oct 05
H&R Wasag AG to Report Fiscal Year 2009 Results on 03/30/2010 H&R Wasag AG announced that they will report fiscal year 2009 results on 03/30/2010 Is New 90 Day High Low • Sep 26
New 90-day low: €5.14 The company is down 1.0% from its price of €5.21 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.44 per share.